Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

32.34 +1.08 (+3.47%)

Delayed Quote Updated: 11:57 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast ↗

December 23, 2021

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital...

Via Benzinga

Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review ↗

December 23, 2021

The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and...

Via Benzinga

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

5 Stocks To Watch For December 23, 2021 ↗

December 23, 2021

Some of the stocks that may grab investor focus today are: Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of...

Via Benzinga

Is Now the Time to Bet on Arcutis Biotherapeutics? ↗

September 18, 2021

Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

Via The Motley Fool

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study ↗

July 01, 2021

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo. The study was ...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021 ↗

June 30, 2021

Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021 ↗

May 27, 2021

Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80...

Via Benzinga

55 Biggest Movers From Friday ↗

May 03, 2021

Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 30, 2021

Gainers Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 30.17% to $1.42 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of...

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

April 30, 2021

Gainers Image Sensing Systems, Inc. (NASDAQ: ISNS) rose 29.2% to $5.93 after the company announced it initiated a quarterly dividend of $0.12 per share, authorized a 220,000...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 30, 2021

Gainers Motus GI Hldgs (NASDAQ:MOTS) stock increased by 46.78% to $1.6 during Friday's pre-market session. The market value of their outstanding shares is at $74.7...

Via Benzinga

Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation ↗

April 23, 2021

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.